Drug Profile
Research programme: parasitic infections therapeutics - Astellas/DNDi
Alternative Names: Tropical disease therapies - Astellas/DNDiLatest Information Update: 28 Dec 2022
Price :
$50
*
At a glance
- Originator Astellas Pharma
- Developer Astellas Pharma; Drugs for Neglected Diseases Initiative Foundation
- Class Antiprotozoals; Small molecules
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported African trypanosomiasis; Chagas disease; Leishmaniasis
Most Recent Events
- 28 Dec 2022 No recent reports of development identified for research development in Chagas-disease in Switzerland
- 28 Dec 2022 No recent reports of development identified for research development in Leishmaniasis in Switzerland
- 26 Nov 2018 Early research in Chagas disease and Leishmaniasis is ongoing in Switzerland (DNDi website, November 2018)